報價延遲最少15分鐘:2025/08/25 23:04 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.67 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.81/-1.88
|
|
企業價值
257.05M
|
| 資產負債 |
|
每股賬面淨值
6.29
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
135.44M
|
|
每股收益
2.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/08/25 23:04 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platformsdesigned by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific. |
